National Science Foundation Awards Vitanova Biomedical a $225,000 Grant: Funds Allow for Research and Development on the Company’s Light-Activated Intracellular Acidosis

Vitanova Biomedical, a San Antonio, Texas-based biotechnology company dedicated to improving the lives of cancer patients and the healthcare professionals who care for them, has been awarded a National Science Foundation (NSF) SBIR grant for $225,000 to conduct research and development (R&D) work on the company’s light-activated intracellular acidosis (LAIA) targeted cancer therapy.

Vitanova Biomedical is developing a prostate-specific membrane antigen targeted drug, VNBp-1, formulated as a first-line treatment for local stage prostate cancer. Light-activated VNBp-1 is designed as an effective alternative to the current standard of care treatments, with the potential to eliminate the unwanted side effects of current cancer treatments. VNB will exclusively utilize LiteCure Medical Lasers’ medical laser technology as the energy source to activate its proprietary drug.

“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF.

“This NSF SBIR Phase I award will significantly advance the development of our LAIA targeted cancer therapy by funding our planned proof-of-principle studies,” added Dr. Matthew Gdovin, VNB Founder, and Chief Science Officer.

Once a small business is awarded a Phase I SBIR grant (up to $256,000), it becomes eligible to apply for a Phase II grant (up to $1,000,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales. All proposals submitted to the NSF SBIR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. To learn more about America’s Seed Fund powered by NSF, visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis...
The collaborative study between Sheffield Hallam University and aims to gain a better understanding of Alzheimer's Disease (AD) in order to identify those more at risk of developing the disease, so enabling the provision of appropriate interventions much earlier in the disease pathology.
Today they announced that twelve new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups that can improve human and planetary health.
Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.

By using this website you agree to accept Medical Device News Magazine Privacy Policy